However, considering the existence of MM cell subpopulations with markedly different levels of CD46 and CD59, it is more likely that mAb/NHS treatment was selected for CD46high and CD59high populations, which then contributed to the resistant MM phenotype in the second round of mAb/NHS treatment. Here, CD46 is linked to Miyoshi myopathy.